W World Corp. (WWHC)
W World Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in North Las Vegas, NV, US. The stock last traded at $0.80, down 20.00% on the session, giving a market capitalisation of $80.2M. On trailing twelve-month figures it carries a trailing P/E of -8000.00, a net margin of 0.0%. Its beta of 0.64 implies it has historically moved less than the broad market.
W World Corp. is a biopharmaceutical firm dedicated to identifying and advancing innovative treatments for various metabolic and neurological conditions. Its research and development efforts specifically target ailments related to the brain-gut axis, pain and inflammation, autoimmune diseases, and gout. The company's pipeline features two primary experimental drugs: Levotofisopam, currently in clinical trials as a non-sedative therapy for Gout, and Dextofisopam, a non-serotonergic compound that has successfully concluded Phase IIa and Phase IIb clinical trials for irritable bowel syndrome (IBS). Established in 1990, W World Corp. maintains its corporate headquarters in North Las Vegas, Nevada.
W World Corp. is most often compared with the following Financial Services names: